$IRMD
IRADIMED CORP

2024 Q4 Form 10-Q Financial Statement

#000155837024014056 Filed on October 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $18.33M $16.50M
YoY Change 11.04% 23.1%
Cost Of Revenue $4.134M $3.667M
YoY Change 12.73% 28.02%
Gross Profit $14.19M $12.84M
YoY Change 10.55% 21.77%
Gross Profit Margin 77.44% 77.78%
Selling, General & Admin $7.763M $6.479M
YoY Change 19.81% 9.47%
% of Gross Profit 54.7% 50.47%
Research & Development $639.5K $452.6K
YoY Change 41.3% -7.95%
% of Gross Profit 4.51% 3.53%
Depreciation & Amortization $139.8K $190.0K
YoY Change -26.4% 33.44%
% of Gross Profit 0.99% 1.48%
Operating Expenses $8.403M $6.932M
YoY Change 21.21% 8.14%
Operating Profit $5.789M $5.905M
YoY Change -1.97% 42.91%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $629.2K $503.2K
YoY Change 25.04% 378.4%
Pretax Income $6.418M $6.409M
YoY Change 0.15% 51.23%
Income Tax $1.369M $1.341M
% Of Pretax Income 21.33% 20.93%
Net Earnings $5.049M $5.067M
YoY Change -0.35% 47.86%
Net Earnings / Revenue 27.55% 30.7%
Basic Earnings Per Share $0.40 $0.40
Diluted Earnings Per Share $0.40 $0.40
COMMON SHARES
Basic Shares Outstanding 12.67M 12.67M 12.60M
Diluted Shares Outstanding 12.78M 12.74M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.72M $46.75M
YoY Change 10.63% -15.91%
Cash & Equivalents $51.72M $46.75M
Short-Term Investments
Other Short-Term Assets $948.8K $740.0K
YoY Change 28.22% 91.4%
Inventory $11.25M $11.67M
Prepaid Expenses
Receivables $10.36M $12.78M
Other Receivables $0.00 $0.00
Total Short-Term Assets $74.29M $71.93M
YoY Change 3.27% 0.08%
LONG-TERM ASSETS
Property, Plant & Equipment $14.16M $8.888M
YoY Change 59.27% 287.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $184.2K $177.7K
YoY Change 3.69% -24.78%
Total Long-Term Assets $19.96M $15.47M
YoY Change 28.99% 101.73%
TOTAL ASSETS
Total Short-Term Assets $74.29M $71.93M
Total Long-Term Assets $19.96M $15.47M
Total Assets $94.25M $87.41M
YoY Change 7.83% 9.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.401M $2.783M
YoY Change -49.67% 188.57%
Accrued Expenses $3.739M $2.810M
YoY Change 33.07% -0.38%
Deferred Revenue $2.555M $1.924M
YoY Change 32.79% 21.3%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.063M $7.882M
YoY Change 2.3% 40.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.751M $4.960M
YoY Change -44.53% 18.96%
Total Long-Term Liabilities $2.751M $4.960M
YoY Change -44.53% 18.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.063M $7.882M
Total Long-Term Liabilities $2.751M $4.960M
Total Liabilities $10.81M $12.84M
YoY Change -15.77% 31.36%
SHAREHOLDERS EQUITY
Retained Earnings $53.55M $46.69M
YoY Change 14.67% 7.12%
Common Stock $1.267K $1.260K
YoY Change 0.56% 0.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $83.43M $74.57M
YoY Change
Total Liabilities & Shareholders Equity $94.25M $87.41M
YoY Change 7.83% 9.88%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income $5.049M $5.067M
YoY Change -0.35% 47.86%
Depreciation, Depletion And Amortization $139.8K $190.0K
YoY Change -26.4% 33.44%
Cash From Operating Activities $9.116M $1.390M
YoY Change 555.81% -64.71%
INVESTING ACTIVITIES
Capital Expenditures $4.011M $430.0K
YoY Change 832.9% -177.31%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$4.011M -$430.0K
YoY Change 832.9% -22.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.918M -30.00K
YoY Change 6294.37% -157.32%
NET CHANGE
Cash From Operating Activities 9.116M 1.390M
Cash From Investing Activities -4.011M -430.0K
Cash From Financing Activities -1.918M -30.00K
Net Change In Cash 3.186M 930.0K
YoY Change 242.57% -72.92%
FREE CASH FLOW
Cash From Operating Activities $9.116M $1.390M
Capital Expenditures $4.011M $430.0K
Free Cash Flow $5.104M $960.0K
YoY Change 431.69% -78.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001325618
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12669912
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12660313
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36534
dei Entity Registrant Name
EntityRegistrantName
IRADIMED CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
73-1408526
dei Entity Address Address Line1
EntityAddressAddressLine1
1025 Willa Springs Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Winter Springs
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32708
dei City Area Code
CityAreaCode
407
dei Local Phone Number
LocalPhoneNumber
677-8022
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001
dei Trading Symbol
TradingSymbol
IRMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12673441
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51721051
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49762198
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
277437
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
368835
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10364786
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12224273
CY2024Q3 us-gaap Inventory Net
InventoryNet
11251549
CY2023Q4 us-gaap Inventory Net
InventoryNet
12821194
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
948841
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1193447
CY2024Q3 us-gaap Assets Current
AssetsCurrent
74286227
CY2023Q4 us-gaap Assets Current
AssetsCurrent
76001112
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14155985
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9288625
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2891657
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2519053
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
264075
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2043043
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2464604
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2122816
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
184213
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
181449
CY2024Q3 us-gaap Assets
Assets
94246761
CY2023Q4 us-gaap Assets
Assets
92156098
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1400544
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1857091
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3284226
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2775103
CY2024Q3 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
193688
CY2023Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
103241
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
118203
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
117463
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2555105
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2570407
CY2023Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
7975997
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
261244
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
427963
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
250000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
250000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
250041
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8063010
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16327306
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2748295
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2793548
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2831
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1615080
CY2024Q3 us-gaap Liabilities
Liabilities
10814136
CY2023Q4 us-gaap Liabilities
Liabilities
20735934
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
31500000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
31500000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12669912
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12669912
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12660313
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12660313
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1267
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1265
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
29886087
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
28160745
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
53545271
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
43258154
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
83432625
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
71420164
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94246761
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92156098
CY2024Q3 us-gaap Revenues
Revenues
18325959
CY2023Q3 us-gaap Revenues
Revenues
16504640
us-gaap Revenues
Revenues
53852954
us-gaap Revenues
Revenues
48110120
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
4134253
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
3667256
us-gaap Cost Of Revenue
CostOfRevenue
12263932
us-gaap Cost Of Revenue
CostOfRevenue
11364791
CY2024Q3 us-gaap Gross Profit
GrossProfit
14191706
CY2023Q3 us-gaap Gross Profit
GrossProfit
12837384
us-gaap Gross Profit
GrossProfit
41589022
us-gaap Gross Profit
GrossProfit
36745329
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3967799
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3615020
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12063971
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10848611
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3795320
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2864469
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11098945
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8812872
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
639467
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
452555
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2261596
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2208221
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
8402586
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6932044
us-gaap Operating Expenses
OperatingExpenses
25424512
us-gaap Operating Expenses
OperatingExpenses
21869704
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
5789120
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
5905340
us-gaap Operating Income Loss
OperatingIncomeLoss
16164510
us-gaap Operating Income Loss
OperatingIncomeLoss
14875625
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
629201
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
503192
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1766572
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1180988
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6418321
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6408532
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
17931082
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16056613
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1368830
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1341352
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3843834
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3403523
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
5049491
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5067180
us-gaap Net Income Loss
NetIncomeLoss
14087248
us-gaap Net Income Loss
NetIncomeLoss
12653090
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.99
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12669741
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12602581
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12665743
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12597250
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12778446
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12735837
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12762346
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12716988
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
71420164
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
4136533
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
628640
CY2024Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-63875
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
76121462
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
4901224
CY2024Q2 irmd Dividends Paid Amount Per Share
DividendsPaidAmountPerShare
0.15
CY2024Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1899644
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
609096
CY2024Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-63945
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3296
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
79671489
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
5049491
CY2024Q3 irmd Dividends Paid Amount Per Share
DividendsPaidAmountPerShare
0.15
CY2024Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1900487
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
629965
CY2024Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-17833
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
83432625
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
73672987
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
3406070
CY2023Q1 irmd Dividends Paid Amount Per Share
DividendsPaidAmountPerShare
1.05
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
13222907
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
533643
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-49878
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
64339915
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
4179840
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
568453
CY2023Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-97105
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7339
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
68998442
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5067180
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
533749
CY2023Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-31372
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
74568000
us-gaap Profit Loss
ProfitLoss
14087248
us-gaap Profit Loss
ProfitLoss
12653090
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-91398
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
136830
us-gaap Inventory Write Down
InventoryWriteDown
202140
us-gaap Inventory Write Down
InventoryWriteDown
219928
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
622790
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
559805
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3872
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12535
us-gaap Share Based Compensation
ShareBasedCompensation
1867701
us-gaap Share Based Compensation
ShareBasedCompensation
1635845
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
591829
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1102866
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1950885
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-343054
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1278208
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6130592
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-244606
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
40055
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2764
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-418274
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-473820
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
519648
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
509123
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-581699
us-gaap Increase Decrease In Property And Other Taxes Payable
IncreaseDecreaseInPropertyAndOtherTaxesPayable
90447
us-gaap Increase Decrease In Property And Other Taxes Payable
IncreaseDecreaseInPropertyAndOtherTaxesPayable
-18696
irmd Increase Decrease In Warranty Reserve
IncreaseDecreaseInWarrantyReserve
740
irmd Increase Decrease In Warranty Reserve
IncreaseDecreaseInWarrantyReserve
16274
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-60555
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
407064
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
250000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
254093
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
19637394
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
9552532
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5214859
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6908607
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
545198
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
465744
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5760057
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7374351
us-gaap Payments Of Dividends
PaymentsOfDividends
11776128
us-gaap Payments Of Dividends
PaymentsOfDividends
13222907
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3296
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7341
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
145652
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
178355
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-11918484
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13393921
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1958853
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11215740
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49762198
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57960864
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51721051
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46745124
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4456827
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4136152
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
227983
irmd Operating Lease Right Of Use Asset And Liability Adjustment
OperatingLeaseRightOfUseAssetAndLiabilityAdjustment
1486093
irmd Operating And Short Term Lease Payments
OperatingAndShortTermLeasePayments
612910
irmd Operating And Short Term Lease Payments
OperatingAndShortTermLeasePayments
492528
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain Significant Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We market our products to end users in the United States and to third-party distributors internationally. Sales to end users in the United States are generally made on open credit terms. Management maintains an allowance for potential credit losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have deposited our cash and cash equivalents with various financial institutions. Our cash and cash equivalents balances exceed federally insured limits regularly throughout the year. We have not incurred any losses related to these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our medical devices require clearance from the FDA and international regulatory agencies prior to commercialized sales. Our future products may not receive required approvals. If we were denied such approvals, or if such approvals were revoked or delayed or if we were unable to timely renew certain approvals for existing products, it would have a materially adverse impact on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain key components of our products essential to their functionality are sole-sourced. Any disruption in the availability of these components would have a materially adverse impact on our business, results of operations and financial condition.</p>
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18325959
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16504640
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53852954
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48110120
CY2024Q3 irmd Revenue From Contract With Customer Before Other Income Excluding Assessed Tax
RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax
13006675
CY2023Q3 irmd Revenue From Contract With Customer Before Other Income Excluding Assessed Tax
RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax
11782829
irmd Revenue From Contract With Customer Before Other Income Excluding Assessed Tax
RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax
37608538
irmd Revenue From Contract With Customer Before Other Income Excluding Assessed Tax
RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax
33150529
CY2024Q3 irmd Revenue From Disposables And Services
RevenueFromDisposablesAndServices
4735066
CY2023Q3 irmd Revenue From Disposables And Services
RevenueFromDisposablesAndServices
4213666
irmd Revenue From Disposables And Services
RevenueFromDisposablesAndServices
14604879
irmd Revenue From Disposables And Services
RevenueFromDisposablesAndServices
13464278
CY2024Q3 irmd Amortization Of Extended Warranty Agreements
AmortizationOfExtendedWarrantyAgreements
584218
CY2023Q3 irmd Amortization Of Extended Warranty Agreements
AmortizationOfExtendedWarrantyAgreements
508145
irmd Amortization Of Extended Warranty Agreements
AmortizationOfExtendedWarrantyAgreements
1639537
irmd Amortization Of Extended Warranty Agreements
AmortizationOfExtendedWarrantyAgreements
1495313
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18325959
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16504640
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53852954
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48110120
CY2024Q3 irmd Advance Payments From Customers
AdvancePaymentsFromCustomers
216097
CY2023Q4 irmd Advance Payments From Customers
AdvancePaymentsFromCustomers
508956
CY2024Q3 irmd Shipments In Transit
ShipmentsInTransit
166700
CY2023Q4 irmd Shipments In Transit
ShipmentsInTransit
15438
CY2024Q3 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
4920603
CY2023Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
4835966
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5303400
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5360360
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5360360
irmd Contract With Customer Liability Increase Due To Cash Received From Customers
ContractWithCustomerLiabilityIncreaseDueToCashReceivedFromCustomers
3353763
irmd Contract With Customer Liability Decrease Due To Recognition Of Revenue
ContractWithCustomerLiabilityDecreaseDueToRecognitionOfRevenue
3410723
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5303400
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4748319
irmd Contract With Customer Liability Increase Due To Cash Received From Customers
ContractWithCustomerLiabilityIncreaseDueToCashReceivedFromCustomers
3716326
irmd Contract With Customer Liability Decrease Due To Recognition Of Revenue
ContractWithCustomerLiabilityDecreaseDueToRecognitionOfRevenue
3309262
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5155383
CY2024Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
164898
CY2023Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
162134
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
5049491
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5067180
us-gaap Net Income Loss
NetIncomeLoss
14087248
us-gaap Net Income Loss
NetIncomeLoss
12653090
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12669741
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12602581
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12665743
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12597250
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2104
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
18727
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2223
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
18860
CY2024Q3 irmd Incremental Common Shares Attributable To Dilutive Effect Of Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits
63929
CY2023Q3 irmd Incremental Common Shares Attributable To Dilutive Effect Of Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits
73478
irmd Incremental Common Shares Attributable To Dilutive Effect Of Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits
55870
irmd Incremental Common Shares Attributable To Dilutive Effect Of Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits
63300
CY2024Q3 irmd Incremental Common Shares Attributable To Dilutive Effect Of Performance Based Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceBasedRestrictedStockUnits
42672
CY2023Q3 irmd Incremental Common Shares Attributable To Dilutive Effect Of Performance Based Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceBasedRestrictedStockUnits
41051
irmd Incremental Common Shares Attributable To Dilutive Effect Of Performance Based Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceBasedRestrictedStockUnits
38510
irmd Incremental Common Shares Attributable To Dilutive Effect Of Performance Based Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceBasedRestrictedStockUnits
37578
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12778446
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12735837
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12762346
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12716988
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.99
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
438
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
352
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
9700270
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
10833004
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
703363
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
501191
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1470786
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1907729
CY2024Q3 us-gaap Inventory Gross
InventoryGross
11874419
CY2023Q4 us-gaap Inventory Gross
InventoryGross
13241924
CY2024Q3 us-gaap Inventory Adjustments
InventoryAdjustments
622870
CY2023Q4 us-gaap Inventory Adjustments
InventoryAdjustments
420730
CY2024Q3 us-gaap Inventory Net
InventoryNet
11251549
CY2023Q4 us-gaap Inventory Net
InventoryNet
12821194
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18616142
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13358460
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4460157
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4069835
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14155985
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9288625
CY2024Q3 us-gaap Depreciation
Depreciation
139840
CY2023Q3 us-gaap Depreciation
Depreciation
164595
us-gaap Depreciation
Depreciation
450194
us-gaap Depreciation
Depreciation
484094
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14155985
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9288625
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4016282
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3471085
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1124625
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
952032
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2891657
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2519053
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
57731
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
25236
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
25236
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
172596
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
75708
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
59518
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
235703
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
223987
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
150274
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
147672
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
290780
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
629964
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
533748
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1867701
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1635845
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1368830
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3843834
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.213
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.214
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1341352
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3403523
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.209
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.212
CY2024Q3 irmd Number Of Material Lease Contracts
NumberOfMaterialLeaseContracts
2
us-gaap Lessee Operating Lease Existence Of Residual Value Guarantee
LesseeOperatingLeaseExistenceOfResidualValueGuarantee
false
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
160266
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
157982
us-gaap Operating Lease Cost
OperatingLeaseCost
479561
us-gaap Operating Lease Cost
OperatingLeaseCost
466591
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
152972
CY2024Q3 irmd Lessee Operating Lease Liability Payments Due After Year One
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne
173514
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
326486
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
62411
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
264075
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
6921468
CY2023Q4 us-gaap Purchase Obligation
PurchaseObligation
8217571
CY2024Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
250000
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
250000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001558370-24-014056-index-headers.html Edgar Link pending
0001558370-24-014056-index.html Edgar Link pending
0001558370-24-014056.txt Edgar Link pending
0001558370-24-014056-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
irmd-20240930.xsd Edgar Link pending
irmd-20240930x10q.htm Edgar Link pending
irmd-20240930xex31d1.htm Edgar Link pending
irmd-20240930xex31d2.htm Edgar Link pending
irmd-20240930xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
irmd-20240930_cal.xml Edgar Link unprocessable
irmd-20240930_def.xml Edgar Link unprocessable
irmd-20240930_lab.xml Edgar Link unprocessable
irmd-20240930_pre.xml Edgar Link unprocessable
irmd-20240930x10q_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending